Supercharge your business growth to outperform competitors using our custom business development playbook and proprietary global marketing networks.

Innovation IdeasGeneric Prescription Drugs

Portfolio Consulting Services

Innovation IdeasIntroductionThe generic industry is changing rapidly; some markets are consolidating to cope with slowing growth, others are exploding as population wealth rises. Big pharma is now a major player in the generic sector. Governments are pushing through Rx to OTC switches in order to reduce their drug budgets in chronic illnesses.In fast growth markets, governments are creating protectionist environments, seeking to develop local manufacturing whilst also ensuring they are not dependent on any particular country or company for imports. All in all, to prosper in the generic industry of tomorrow, new ideas need to be considered.

This presentation is a simple report on ideas that Generic Pharma 2.0 have been asked to research by various clients. A summary of differentiation possibilities, without consideration for technical or economic viability. At Generic Pharma 2.0 we call this: Pharmagination.

Our contact details can be found at the end of this presentation; we’d love to run an ideation session with you.

Asa Cox, CEO & Founder

SummaryPatients- Engagement, services, customisation- Innovation requires commitment

Products- World is oyster, blank canvass- Innovation requires investment

Price- Incremental, organisational- Innovation requires scale

Partners- Integration, co-invention, services- Innovation requires collaboration

PatientsDose Management/Compliance- Data collection: Home dispensing recorders- Monitoring: Patient communication systems/service- Intelligent Packaging: Dose regimen notifications- Reminders: Integrated with MHR, insurance, pharmacies- Dispensing systems: Multi-drug machines- Education: Content systems to reduce intentional non-adherence- Labels: Clarity, Weight/dose information

- Engagement, services, customisation- Innovation requires commitment

PatientsSafety- Child & Geriatric best practice: pack design, readability- Anti-counterfeiting: digital verification, hologram- Dose form: stamps, coating, colour, taste- Dosing: Part doses (also patient cost reduction)- Abuse deterrents: Non-crushable, irritants, antidote combo, bio-activated

- Engagement, services, customisation- Innovation requires commitment

ProductsFirst to market- Orphan drugs: new indication for old molecule (<clinical + >safety)

- Patent challenges: salts, alternative formulations (505b2), invalidity, data mining, Canadian partner of choice (Finances - litigation funding, at-risk launch insurance)

- Reformulation: SR/ER, Pegylation/Liposomes, >stability (global req.), bioavailability (reduce volume), fast acting (ODT, thinstrip), solid to liquid, semi-solid to patch/tape, phase release (early morning, mid sleep etc)

"Is it valuable to the patient, valuable to the physician or valuable to the health providers/insurance companies"

- World is oyster, blank canvass- Innovation requires investment

ProductsPatient Centric- Convenience: Films, liquids, unit dose, direct-to-mouth, patch/tape Regimen/patient packs (blisters vs bottles)

- Preference: Foam or spray vs cream/gel/ointment Size - "bigger is better" vs easy-to-swallow

- World is oyster, blank canvass- Innovation requires investment

PriceR&D - Optimisation (market vs manufacturing vs resources vs strategy)- Venture capital/Darwinian view of project approval

Manufacturing- Complexity/variant management (esp. with PSI): Batch changes, packaging, stock etc Regional packaging hubs for PSI- Continuous manufacturing- Manufacturing techniques e.g Foam (vs wet) granulation

- Incremental, organisational- Innovation requires scale

PriceSourcing/Supply-Chain/Purchasing- China/India sourcing office- API R&D price reduction exchange for royalty (subject to timetable, patents etc)- Co-development (cost/profit sharing) for higher risk (competition, time, costs, reg.)- Co-invention projects for global exploitation- Global benchmarking ('local' price = future regulated price)- Sourcing/purchasing plaforms, e.g io-pharma.com

Organisation- Outsource R&D for certain projects (sponsor/FTE projects)- R&D organisation best practice for productivity (definition?)

- Incremental, organisational- Innovation requires scale

PartnersInternational- Patient services: improve awareness, loyalty, preference. 'Canada quality'- Products: First to market, support 'early' launch (patent breaking)- Price: Local 'manufacturing', regional CMO's (vs 'made in Canada'?)

Domestic- Dis-intermediation (direct to pharmacy + support contract flexible buyers)- Online pharmacy (direct to patient)- Out of stock insurance (financial)

Both- Anti-counterfeiting 'services'- Pharmacy education (product reformulation, value add etc)- Information for pharmacies (availability, new products, patents, promotions)

- Integration, co-invention, services- Innovation requires collaboration

About GP2.0Supercharge your business growth to outperform competitors using our custom business development playbook and proprietary global marketing networks.

Masters of business development & marketing “”

Asa Cox, Founder & CEOasa.cox@genericpharma20.com+1 705 615 1500

ServicesOutsourced Business Development

Business Development Planning & StrategyIn/Out Licensing & Partnership Selection

ConsultingPortfolio Development & Optimisation

International Market Entry Planning

Software/WebMarketing Content Creation, Distribution & Monitoring

Lead Generation & Lead Conversion Software

CreativeWeb & Print Design

Established in 2008, Generic Pharma 2.0 has been building a global network of 30,000 companies; achieved by combining ferocious business development and web technologies.

It offers clients both access to its network and the intelligence gained from unique perspective.

We work with companies of all sizes, locations and product categories. We partner with clients. We create together. We have a lot of fun.

Lets start growing!